ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1176

Development and Validation of a Preliminary MRI Sacroiliac Joint Composite Structural Damage Score in a 5-year Longitudinal Study of Patients with Axial Spondyloarthritis

Marie Wetterslev1, Mikkel Østergaard 2, Inge Juul Sørensen 3, Ulrich Weber 4, Anne Gitte Loft 5, Gina Kollerup 6, Lars Juul 6, Gorm Thamsborg 6, Ole Rintek Madsen 7, Jakob Møller 8 and Susanne Juhl Pedersen 3, 1Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, Copenhagen Ø, Hovedstaden, Denmark, 2Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark, 3Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, Copenhagen, Hovedstaden, Denmark, 4Danish Hospital for Rheumatic Diseases, Soenderborg, Denmark, Gråsten, Syddanmark, Denmark, 5Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, Århus, Denmark, 6Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, Copenhagen, Hovedstaden, Denmark, 7Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, Copenhagen, Denmark, 8Department of Radiology, Herlev and Gentofte University Hospital, Herlev, Denmark, Copenhagen, Denmark

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: axial spondyloarthritis and magnetic resonance imaging (MRI)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Title: Imaging Of Rheumatic Diseases Poster II

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: In patients with axial spondyloarthritis (axSpA), MRI reliably detects structural lesions in the sacroiliac joints (SIJs). The SPARCC Sacroiliac joint (SIJ) Structural Score (SSS)(1) is a reliable and validated method to assess the individual structural lesions of the SIJs, i.e. fat lesion, erosion, backfill (fat metaplasia in an erosion cavity) and ankylosis. Several MRI studies have indicated that bone destruction, i.e. erosion, is often followed by formation of new bone in the erosion cavity (backfill), ultimately leading to ankylosis(2). The aim was to combine these lesions into a composite score for SIJ structural damage and to test it in a 5-year follow up study with patients with axSpA.

Methods: Thirty-three patients fulfilling ASAS criteria for axSpA were followed for 5 years after initiation of TNF inhibitor in the BIOSPA study(2). T1-weighted (T1w) and STIR MRI sequences of the SIJs acquired at weeks 0 and 46 and year 2, 3, 4, 5 were evaluated with SPARCC SIJ SSS. In each of 5 slices of each SIJ, erosion is scored 0-1 per joint quadrant (i.e. max score 2 per joint half, 4 per SIJ), backfill scored 0-1 per joint half (i.e. max 2 per SIJ) and ankylosis scored 0-1 per joint half (i.e. max 2 per SIJ). Based on this, a preliminary composite axSpA MRI SIJ Structural Damage Score (CSDS) was calculated: (Erosion score x1) + (backfill score x4) + (ankylosis score x6).

Results: Patients were divided into two groups: patients with almost complete bilateral ankylosis (CSDS≥108, n=10) and patients with no/minimal ankylosis (CSDS< 108, n=23). At baseline patients with CSDS< 108 were younger, had shorter symptom duration, lower BASMI, higher SPARCC Inflammation, lower SSS Fat, Erosion, Backfill and Ankylosis scores, as compared to patients with CSDS≥108. At baseline, CSDS correlated positively with symptom duration, BASMI and SSS Fat and Ankylosis, and negatively with BASDAI and SPARCC inflammation. Change in CSDS over 5 years correlated negatively with change in SPARCC Inflammation and positively with change in SSS Fat and Ankylosis. Change in CSDS over 5 years in patients with no/minimal ankylosis correlated negatively with change in SPARCC Inflammation and positively with change in SSS Fat and Ankylosis. There was no change in the group with almost complete ankylosis at baseline. (Table 1) Table 2 show the annual change CSDS over 5 years. It is noted in Figure 1, that many patients progressed the first 46 weeks, thereafter the progression decreases. However, the mean progression increases in the last year, based on a few patients with markedly increasing scores.

Conclusion: A preliminary Composite Structural Damage Score for MRI assessment of the sacroiliac joints in patients with axial spondyloarthritis, which allows scoring of MRI progression of erosion through backfill to ankylosis, is described for the first time. Progression was most pronounced in the first year after TNF-inhibitor initiation. Further validation is needed. This novel approach may be useful for monitoring structural progression in axSpA patients receiving different therapies.

References:

  1. Maksymowych WP et al. J Rheumatol 2015;42:79-86.
  2. Maksymowych WP et al. Arthritis Rheum 2014;66:2958-67.
  3. Pedersen SJ et al. Scand J Rheumatol 2019;48:185-197.


Table1_ACR19_20190603

Table 1. Baseline characteristics and correlation between clinical/MRI variables and The Composite AxSpA MRI Structural Damage Score for all patients, patients with no/minimal ankylosis -CSDS<108- and patients with almost complete ankylosis -CSDS≥108-.


Table2_ACR19_20190603

Table 2. Annual change in Composite AxSpA MRI SIJ Structural Damage Score -CSDS- for the sacroiliac joints


Figure1_ACR2019_20190603

Figure 1. Composite AxSpA MRI SIJ Structural Damage Score -CSDS- over 5 years in patients with no/minimal ankylosis -CSDS<108-.


Disclosure: M. Wetterslev, None; M. Østergaard, AbbVie, 2, 8, 9, Abbvie, 2, 5, 8, Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli Lilly, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, UCB, 5, 8, Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, and UCB, 5, 8, Abbvie, Celgene, Centocor, Merck, and Novartis, 2, Abbvie, Celgene, Centocor, Merck, Novartis, 2, BMS, 2, 5, 8, 9, Boehringer Ingelheim, 5, 8, Boehringer-Ingelheim, 2, 8, Boehringer-ingelheim, 9, Celgene, 2, 5, 8, Centocor, 2, Eli Lilly, 5, 8, 9, Eli Lilly and Company, 5, 8, Eli-Lilly, 2, 8, Hospira, 2, 5, 8, Janssen, 2, 5, 8, 9, Merck, 2, 5, 8, 9, Novartis, 2, 5, 8, Novo, 2, 5, 8, Novo Nordisk, 5, 8, Orion, 2, 5, 8, Pfizer, 2, 5, 8, 9, Regeneron, 2, 5, 8, Roche, 2, 5, 8, roche, 9, Sandoz, 2, 8, Sanofi, 2, 8, UCB, 2, 5, 8; I. Juul Sørensen, None; U. Weber, None; A. Loft, None; G. Kollerup, None; L. Juul, None; G. Thamsborg, None; O. Rintek Madsen, None; J. Møller, None; S. Juhl Pedersen, None.

To cite this abstract in AMA style:

Wetterslev M, Østergaard M, Juul Sørensen I, Weber U, Loft A, Kollerup G, Juul L, Thamsborg G, Rintek Madsen O, Møller J, Juhl Pedersen S. Development and Validation of a Preliminary MRI Sacroiliac Joint Composite Structural Damage Score in a 5-year Longitudinal Study of Patients with Axial Spondyloarthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/development-and-validation-of-a-preliminary-mri-sacroiliac-joint-composite-structural-damage-score-in-a-5-year-longitudinal-study-of-patients-with-axial-spondyloarthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/development-and-validation-of-a-preliminary-mri-sacroiliac-joint-composite-structural-damage-score-in-a-5-year-longitudinal-study-of-patients-with-axial-spondyloarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology